Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study.
<h4>Background</h4>The ε4 allele of apolipoprotein E (APOE) gene and increasing age are two of the most important known risk factors for developing Alzheimer disease (AD). The diagnosis of AD based on clinical symptoms alone is known to have poor specificity; recently developed diagnosti...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2020-08-01
|
| Series: | PLoS Medicine |
| Online Access: | https://doi.org/10.1371/journal.pmed.1003289 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849332170022191104 |
|---|---|
| author | Hana Saddiki Aurore Fayosse Emmanuel Cognat Séverine Sabia Sebastiaan Engelborghs David Wallon Panagiotis Alexopoulos Kaj Blennow Henrik Zetterberg Lucilla Parnetti Inga Zerr Peter Hermann Audrey Gabelle Mercè Boada Adelina Orellana Itziar de Rojas Matthieu Lilamand Maria Bjerke Christine Van Broeckhoven Lucia Farotti Nicola Salvadori Janine Diehl-Schmid Timo Grimmer Claire Hourregue Aline Dugravot Gaël Nicolas Jean-Louis Laplanche Sylvain Lehmann Elodie Bouaziz-Amar Alzheimer’s Disease Neuroimaging Initiative Jacques Hugon Christophe Tzourio Archana Singh-Manoux Claire Paquet Julien Dumurgier |
| author_facet | Hana Saddiki Aurore Fayosse Emmanuel Cognat Séverine Sabia Sebastiaan Engelborghs David Wallon Panagiotis Alexopoulos Kaj Blennow Henrik Zetterberg Lucilla Parnetti Inga Zerr Peter Hermann Audrey Gabelle Mercè Boada Adelina Orellana Itziar de Rojas Matthieu Lilamand Maria Bjerke Christine Van Broeckhoven Lucia Farotti Nicola Salvadori Janine Diehl-Schmid Timo Grimmer Claire Hourregue Aline Dugravot Gaël Nicolas Jean-Louis Laplanche Sylvain Lehmann Elodie Bouaziz-Amar Alzheimer’s Disease Neuroimaging Initiative Jacques Hugon Christophe Tzourio Archana Singh-Manoux Claire Paquet Julien Dumurgier |
| author_sort | Hana Saddiki |
| collection | DOAJ |
| description | <h4>Background</h4>The ε4 allele of apolipoprotein E (APOE) gene and increasing age are two of the most important known risk factors for developing Alzheimer disease (AD). The diagnosis of AD based on clinical symptoms alone is known to have poor specificity; recently developed diagnostic criteria based on biomarkers that reflect underlying AD neuropathology allow better assessment of the strength of the associations of risk factors with AD. Accordingly, we examined the global and age-specific association between APOE genotype and AD by using the A/T/N classification, relying on the cerebrospinal fluid (CSF) levels of β-amyloid peptide (A, β-amyloid deposition), phosphorylated tau (T, pathologic tau), and total tau (N, neurodegeneration) to identify patients with AD.<h4>Methods and findings</h4>This case-control study included 1,593 white AD cases (55.4% women; mean age 72.8 [range = 44-96] years) with abnormal values of CSF biomarkers from nine European memory clinics and the American Alzheimer's Disease Neuroimaging Initiative (ADNI) study. A total of 11,723 dementia-free controls (47.1% women; mean age 65.6 [range = 44-94] years) were drawn from two longitudinal cohort studies (Whitehall II and Three-City), in which incident cases of dementia over the follow-up were excluded from the control population. Odds ratio (OR) and population attributable fraction (PAF) for AD associated with APOE genotypes were determined, overall and by 5-year age categories. In total, 63.4% of patients with AD and 22.6% of population controls carried at least one APOE ε4 allele. Compared with non-ε4 carriers, heterozygous ε4 carriers had a 4.6 (95% confidence interval 4.1-5.2; p < 0.001) and ε4/ε4 homozygotes a 25.4 (20.4-31.2; p < 0.001) higher OR of AD in unadjusted analysis. This association was modified by age (p for interaction < 0.001). The PAF associated with carrying at least one ε4 allele was greatest in the 65-70 age group (69.7%) and weaker before 55 years (14.2%) and after 85 years (22.6%). The protective effect of APOE ε2 allele for AD was unaffected by age. Main study limitations are that analyses were based on white individuals and AD cases were drawn from memory centers, which may not be representative of the general population of patients with AD.<h4>Conclusions</h4>In this study, we found that AD diagnosis based on biomarkers was associated with APOE ε4 carrier status, with a higher OR than previously reported from studies based on only clinical AD criteria. This association differs according to age, with the strongest effect at 65-70 years. These findings highlight the need for early interventions for dementia prevention to mitigate the effect of APOE ε4 at the population level. |
| format | Article |
| id | doaj-art-74a1e759891e4a0f8f6e13431df2b322 |
| institution | Kabale University |
| issn | 1549-1277 1549-1676 |
| language | English |
| publishDate | 2020-08-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Medicine |
| spelling | doaj-art-74a1e759891e4a0f8f6e13431df2b3222025-08-20T03:46:17ZengPublic Library of Science (PLoS)PLoS Medicine1549-12771549-16762020-08-01178e100328910.1371/journal.pmed.1003289Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study.Hana SaddikiAurore FayosseEmmanuel CognatSéverine SabiaSebastiaan EngelborghsDavid WallonPanagiotis AlexopoulosKaj BlennowHenrik ZetterbergLucilla ParnettiInga ZerrPeter HermannAudrey GabelleMercè BoadaAdelina OrellanaItziar de RojasMatthieu LilamandMaria BjerkeChristine Van BroeckhovenLucia FarottiNicola SalvadoriJanine Diehl-SchmidTimo GrimmerClaire HourregueAline DugravotGaël NicolasJean-Louis LaplancheSylvain LehmannElodie Bouaziz-AmarAlzheimer’s Disease Neuroimaging InitiativeJacques HugonChristophe TzourioArchana Singh-ManouxClaire PaquetJulien Dumurgier<h4>Background</h4>The ε4 allele of apolipoprotein E (APOE) gene and increasing age are two of the most important known risk factors for developing Alzheimer disease (AD). The diagnosis of AD based on clinical symptoms alone is known to have poor specificity; recently developed diagnostic criteria based on biomarkers that reflect underlying AD neuropathology allow better assessment of the strength of the associations of risk factors with AD. Accordingly, we examined the global and age-specific association between APOE genotype and AD by using the A/T/N classification, relying on the cerebrospinal fluid (CSF) levels of β-amyloid peptide (A, β-amyloid deposition), phosphorylated tau (T, pathologic tau), and total tau (N, neurodegeneration) to identify patients with AD.<h4>Methods and findings</h4>This case-control study included 1,593 white AD cases (55.4% women; mean age 72.8 [range = 44-96] years) with abnormal values of CSF biomarkers from nine European memory clinics and the American Alzheimer's Disease Neuroimaging Initiative (ADNI) study. A total of 11,723 dementia-free controls (47.1% women; mean age 65.6 [range = 44-94] years) were drawn from two longitudinal cohort studies (Whitehall II and Three-City), in which incident cases of dementia over the follow-up were excluded from the control population. Odds ratio (OR) and population attributable fraction (PAF) for AD associated with APOE genotypes were determined, overall and by 5-year age categories. In total, 63.4% of patients with AD and 22.6% of population controls carried at least one APOE ε4 allele. Compared with non-ε4 carriers, heterozygous ε4 carriers had a 4.6 (95% confidence interval 4.1-5.2; p < 0.001) and ε4/ε4 homozygotes a 25.4 (20.4-31.2; p < 0.001) higher OR of AD in unadjusted analysis. This association was modified by age (p for interaction < 0.001). The PAF associated with carrying at least one ε4 allele was greatest in the 65-70 age group (69.7%) and weaker before 55 years (14.2%) and after 85 years (22.6%). The protective effect of APOE ε2 allele for AD was unaffected by age. Main study limitations are that analyses were based on white individuals and AD cases were drawn from memory centers, which may not be representative of the general population of patients with AD.<h4>Conclusions</h4>In this study, we found that AD diagnosis based on biomarkers was associated with APOE ε4 carrier status, with a higher OR than previously reported from studies based on only clinical AD criteria. This association differs according to age, with the strongest effect at 65-70 years. These findings highlight the need for early interventions for dementia prevention to mitigate the effect of APOE ε4 at the population level.https://doi.org/10.1371/journal.pmed.1003289 |
| spellingShingle | Hana Saddiki Aurore Fayosse Emmanuel Cognat Séverine Sabia Sebastiaan Engelborghs David Wallon Panagiotis Alexopoulos Kaj Blennow Henrik Zetterberg Lucilla Parnetti Inga Zerr Peter Hermann Audrey Gabelle Mercè Boada Adelina Orellana Itziar de Rojas Matthieu Lilamand Maria Bjerke Christine Van Broeckhoven Lucia Farotti Nicola Salvadori Janine Diehl-Schmid Timo Grimmer Claire Hourregue Aline Dugravot Gaël Nicolas Jean-Louis Laplanche Sylvain Lehmann Elodie Bouaziz-Amar Alzheimer’s Disease Neuroimaging Initiative Jacques Hugon Christophe Tzourio Archana Singh-Manoux Claire Paquet Julien Dumurgier Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study. PLoS Medicine |
| title | Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study. |
| title_full | Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study. |
| title_fullStr | Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study. |
| title_full_unstemmed | Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study. |
| title_short | Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study. |
| title_sort | age and the association between apolipoprotein e genotype and alzheimer disease a cerebrospinal fluid biomarker based case control study |
| url | https://doi.org/10.1371/journal.pmed.1003289 |
| work_keys_str_mv | AT hanasaddiki ageandtheassociationbetweenapolipoproteinegenotypeandalzheimerdiseaseacerebrospinalfluidbiomarkerbasedcasecontrolstudy AT aurorefayosse ageandtheassociationbetweenapolipoproteinegenotypeandalzheimerdiseaseacerebrospinalfluidbiomarkerbasedcasecontrolstudy AT emmanuelcognat ageandtheassociationbetweenapolipoproteinegenotypeandalzheimerdiseaseacerebrospinalfluidbiomarkerbasedcasecontrolstudy AT severinesabia ageandtheassociationbetweenapolipoproteinegenotypeandalzheimerdiseaseacerebrospinalfluidbiomarkerbasedcasecontrolstudy AT sebastiaanengelborghs ageandtheassociationbetweenapolipoproteinegenotypeandalzheimerdiseaseacerebrospinalfluidbiomarkerbasedcasecontrolstudy AT davidwallon ageandtheassociationbetweenapolipoproteinegenotypeandalzheimerdiseaseacerebrospinalfluidbiomarkerbasedcasecontrolstudy AT panagiotisalexopoulos ageandtheassociationbetweenapolipoproteinegenotypeandalzheimerdiseaseacerebrospinalfluidbiomarkerbasedcasecontrolstudy AT kajblennow ageandtheassociationbetweenapolipoproteinegenotypeandalzheimerdiseaseacerebrospinalfluidbiomarkerbasedcasecontrolstudy AT henrikzetterberg ageandtheassociationbetweenapolipoproteinegenotypeandalzheimerdiseaseacerebrospinalfluidbiomarkerbasedcasecontrolstudy AT lucillaparnetti ageandtheassociationbetweenapolipoproteinegenotypeandalzheimerdiseaseacerebrospinalfluidbiomarkerbasedcasecontrolstudy AT ingazerr ageandtheassociationbetweenapolipoproteinegenotypeandalzheimerdiseaseacerebrospinalfluidbiomarkerbasedcasecontrolstudy AT peterhermann ageandtheassociationbetweenapolipoproteinegenotypeandalzheimerdiseaseacerebrospinalfluidbiomarkerbasedcasecontrolstudy AT audreygabelle ageandtheassociationbetweenapolipoproteinegenotypeandalzheimerdiseaseacerebrospinalfluidbiomarkerbasedcasecontrolstudy AT merceboada ageandtheassociationbetweenapolipoproteinegenotypeandalzheimerdiseaseacerebrospinalfluidbiomarkerbasedcasecontrolstudy AT adelinaorellana ageandtheassociationbetweenapolipoproteinegenotypeandalzheimerdiseaseacerebrospinalfluidbiomarkerbasedcasecontrolstudy AT itziarderojas ageandtheassociationbetweenapolipoproteinegenotypeandalzheimerdiseaseacerebrospinalfluidbiomarkerbasedcasecontrolstudy AT matthieulilamand ageandtheassociationbetweenapolipoproteinegenotypeandalzheimerdiseaseacerebrospinalfluidbiomarkerbasedcasecontrolstudy AT mariabjerke ageandtheassociationbetweenapolipoproteinegenotypeandalzheimerdiseaseacerebrospinalfluidbiomarkerbasedcasecontrolstudy AT christinevanbroeckhoven ageandtheassociationbetweenapolipoproteinegenotypeandalzheimerdiseaseacerebrospinalfluidbiomarkerbasedcasecontrolstudy AT luciafarotti ageandtheassociationbetweenapolipoproteinegenotypeandalzheimerdiseaseacerebrospinalfluidbiomarkerbasedcasecontrolstudy AT nicolasalvadori ageandtheassociationbetweenapolipoproteinegenotypeandalzheimerdiseaseacerebrospinalfluidbiomarkerbasedcasecontrolstudy AT janinediehlschmid ageandtheassociationbetweenapolipoproteinegenotypeandalzheimerdiseaseacerebrospinalfluidbiomarkerbasedcasecontrolstudy AT timogrimmer ageandtheassociationbetweenapolipoproteinegenotypeandalzheimerdiseaseacerebrospinalfluidbiomarkerbasedcasecontrolstudy AT clairehourregue ageandtheassociationbetweenapolipoproteinegenotypeandalzheimerdiseaseacerebrospinalfluidbiomarkerbasedcasecontrolstudy AT alinedugravot ageandtheassociationbetweenapolipoproteinegenotypeandalzheimerdiseaseacerebrospinalfluidbiomarkerbasedcasecontrolstudy AT gaelnicolas ageandtheassociationbetweenapolipoproteinegenotypeandalzheimerdiseaseacerebrospinalfluidbiomarkerbasedcasecontrolstudy AT jeanlouislaplanche ageandtheassociationbetweenapolipoproteinegenotypeandalzheimerdiseaseacerebrospinalfluidbiomarkerbasedcasecontrolstudy AT sylvainlehmann ageandtheassociationbetweenapolipoproteinegenotypeandalzheimerdiseaseacerebrospinalfluidbiomarkerbasedcasecontrolstudy AT elodiebouazizamar ageandtheassociationbetweenapolipoproteinegenotypeandalzheimerdiseaseacerebrospinalfluidbiomarkerbasedcasecontrolstudy AT alzheimersdiseaseneuroimaginginitiative ageandtheassociationbetweenapolipoproteinegenotypeandalzheimerdiseaseacerebrospinalfluidbiomarkerbasedcasecontrolstudy AT jacqueshugon ageandtheassociationbetweenapolipoproteinegenotypeandalzheimerdiseaseacerebrospinalfluidbiomarkerbasedcasecontrolstudy AT christophetzourio ageandtheassociationbetweenapolipoproteinegenotypeandalzheimerdiseaseacerebrospinalfluidbiomarkerbasedcasecontrolstudy AT archanasinghmanoux ageandtheassociationbetweenapolipoproteinegenotypeandalzheimerdiseaseacerebrospinalfluidbiomarkerbasedcasecontrolstudy AT clairepaquet ageandtheassociationbetweenapolipoproteinegenotypeandalzheimerdiseaseacerebrospinalfluidbiomarkerbasedcasecontrolstudy AT juliendumurgier ageandtheassociationbetweenapolipoproteinegenotypeandalzheimerdiseaseacerebrospinalfluidbiomarkerbasedcasecontrolstudy |